Skip to main content

Table 1 Characteristics of enrolled studies in diffuse large B-cell lymphoma

From: The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis

author country year cut-off cases antibody Follow-up (month) therapeutic regimen HR (95%CI) of OS HR (95%CI) of PFS
PD-L1+/− clone dilution source
Kiyasu J Japan 2015 0.3 34/239 EPR1161 1:200 Dako 60 80%RCHOP/CHOP-like 1.809
(1.051–3.112)
NA
Xing W America 2016 0.3 14/72 E1L3N NA Cell Signaling 21
(0.067–175)
RCHOP 2.418
(1.031–5.670)
2.130
(1.050–4.330)
Kwon D Korea 2016 0.1 77/49 E1L3N NA Cell Signaling 52
(16–165)
RCHOP 0.430
(0.152–1.217)
NA
Dong L China 2016 0.05 54/46 ab153991 1:200 NA 52.4
(1.5–89.1)
CHOP/CHOP-like+ 39%R 4.740
(1.097–20.477)
NA
Four M France 2016 0.05 12/20 SP142 NA Ventana 17
(1–78)
chemotherapy and/or radiotherapy 7.7
(1.6–37.2)
1.7
(0.67–4.28)
Bledsoe JR America 2016 0.25 20/26 E1L3N 1:200 Cell Signaling 78 RCHOP 0.29
(0.06–1.25)
0.19
(0.04–0.83)
Hu LY China 2017 0.05 100/104 NA 1:50 Cell Signaling 52
(1–114)
RCHOP+ 26.7%RT 4.055
(1.610–10.230)
1.584
(1.000–2.510)
Fang X China 2017 0.1 20/54 SP142 ready to use ZSGB-BIO 2.4–86.4 CHOP/CHOP-like+ 55.2%R 2.547
(0.964–6.730)
NA
Liu Y China 2018 0.3 11/81 SP142 NA NA 58
(1–78)
RCHOP 4.63
(1.53–13.99)
NA
Ishikawa E Japan 2018 0.05 3/48 SP142 NA NA 42
(3.5–150)
86.4%RCHOP 5.72
(1.50–21.8)
NA
Sun C China 2018 0.5 34/253 22C3 NA Dako 76 CHOP/CHOP-like+ 53.7%R 1.494
(0.868–2.571)
NA
Kwon HJ Korea 2018 0.3 23/84 E1L3N 1:100 Cell Signaling NA 86.9%RCHOP/CHOP-like 1.21
(0.15–9.98)
2.21
(0.59–8.27)
Shi YF China 2018 0.3 21/104 SP142 1:100 Ventana 25.7
(0.8–131.1)
58.1%RCHOP/CHOP-like;29.7%surgery NA 0.379
(0.149–0.962)
  1. NA not available; RCHOP rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; RT radiotherapy;HR hazard ratio;CI confidence interval;OS overall
  2. survival; PFS progression-free survival